<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04943419</url>
  </required_header>
  <id_info>
    <org_study_id>Colorectal MDSC</org_study_id>
    <nct_id>NCT04943419</nct_id>
  </id_info>
  <brief_title>Myeloid-derived Suppressor Cells in Colorectal Cancer</brief_title>
  <official_title>Myeloid-derived Suppressor Cells in Colorectal Cancer: Influence on Postoperative Complications and Neoadjuvant Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jagiellonian University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jagiellonian University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate whether the preoperative level of myeloid-derived&#xD;
      suppressor cells is associated with postoperative complications classified by Clavien-Dindo&#xD;
      categories. Levels of all MDSC, polymorphonuclear MDSC (PMNMDSC), monocytic MDSC (MMDSC),&#xD;
      early-stage MDSC (EMDSC) and monocytic to polymorphonuclear MDSC ratio (M/PMN MDCS) were&#xD;
      established and compared in patients with postoperative complications, severe postoperative&#xD;
      complications (&gt;= IIIA according to Clavien-Dindo) and severe septic complications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Levels of all MDSC, polymorphonuclear MDSC (PMNMDSC), monocytic MDSC (MMDSC), early-stage&#xD;
      MDSC (EMDSC) and monocytic to polymorphonuclear MDSC ratio (M/PMN MDCS) were established and&#xD;
      compared in patients with and without postoperative complications. Then subgroup analysis was&#xD;
      performed to compare levels of MDSC in patients with severe postoperative complications (&gt;=&#xD;
      IIIA according to Clavien-Dindo) and those without severe complications. Another subgroup&#xD;
      analysis will be performed for patients with severe septic complications that are defined as&#xD;
      severe complications with accompanying infection. Levels of MDSC will be compared by means of&#xD;
      U Mann Whitney test as their distribution is not normal. After above mentioned analyses it&#xD;
      will be possible to evaluate the role of MDSC in patients with colorectal cancer in terms of&#xD;
      postoperative complications. Additional analyse will be performed to compare levels of MDSC&#xD;
      in patients who underwent neoadjuvant treatment (radiotherapy or chemoradiotherapy).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2016</start_date>
  <completion_date type="Actual">June 21, 2021</completion_date>
  <primary_completion_date type="Actual">February 27, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Level of MDSC in patients with postoperative complications</measure>
    <time_frame>30 days</time_frame>
    <description>Level of all MDSC, polymorphonuclear MDSC (PNMMDSC), monocytic MDSC ( MMDSC), early-stage MDSC (EMDSC) and monocytic to polymorphonuclear MDSC ratio (M/PMNMDSC) in patients with postoperative complications</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Level of MDSC in patients with severe postoperative complications</measure>
    <time_frame>30 days</time_frame>
    <description>Level of all MDSC, PNMMDSC, MMDSC, EMDSC and M/PMNMDSC ratio in patients with severe postoperative complications (Clavien-Dindo&gt;= IIIA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of MDSC in patients with severe septic postoperative complications</measure>
    <time_frame>30 days</time_frame>
    <description>Level of all MDSC, PNMMDSC, MMDSC, EMDSC and M/PMNMDSC ratio in patients with severe postoperative complications (Clavien-Dindo&gt;= IIIA) with infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of MDSC in patients after neoadjuvant therapy</measure>
    <time_frame>1 day before surgery</time_frame>
    <description>Level of all MDSC, PNMMDSC, MMDSC, EMDSC and M/PMNMDSC ratio in patients after neoadjuvant treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of MDSC in patients with T2-T4 tumours after neoadjuvant treatment</measure>
    <time_frame>1 day before surgery</time_frame>
    <description>Level of all MDSC, PNMMDSC, MMDSC, EMDSC and M/PMNMDSC ratio in patients with tumours T2-T4 after neoadjuvant treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of MDSC measured in the specimen</measure>
    <time_frame>1 day</time_frame>
    <description>evel of all MDSC, PNMMDSC, MMDSC, EMDSC and M/PMNMDSC ratio measured in the specimen after resection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of MDSC in patients with left and right sided tumours</measure>
    <time_frame>1 day</time_frame>
    <description>evel of all MDSC, PNMMDSC, MMDSC, EMDSC and M/PMNMDSC ratio measured in patients with left-sided and right-sided colorectal cancer</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">90</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Suppression</condition>
  <condition>Complication,Postoperative</condition>
  <condition>Radiotherapy</condition>
  <arm_group>
    <arm_group_label>Colorectal cancer</arm_group_label>
    <description>Patients with colorectal cancer qualified for elective operations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Level of Myeloid-Derived Suppressor Cells</intervention_name>
    <description>Establishing of levels of all MDSC, PMNMDSC, MMDSC, EMDSC, M/PMN MDSC ratio on the day before operation.</description>
    <arm_group_label>Colorectal cancer</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with histologically-confirmed colorectal cancer who undergo elective surgery.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age â‰¥ 18&#xD;
&#xD;
          -  colorectal cancer confirmed by histological examination of biopsy specimen&#xD;
&#xD;
          -  elective operation&#xD;
&#xD;
          -  signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Emergency operation&#xD;
&#xD;
          -  General condition that precludes understanding and signing of the informed consent&#xD;
             form&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Radoslaw Pach, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jagiellonian University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1st Department of General Surgery</name>
      <address>
        <city>Krakow</city>
        <state>Malopolska</state>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 21, 2021</study_first_submitted>
  <study_first_submitted_qc>June 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2021</study_first_posted>
  <last_update_submitted>June 28, 2021</last_update_submitted>
  <last_update_submitted_qc>June 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jagiellonian University</investigator_affiliation>
    <investigator_full_name>Radoslaw Pach, MD, Ph D</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Postoperative Complications</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

